ScholarIQanswers from OpenAlex

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

PaperCitations, authors & open-access status

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer have?

ScholarIQcitation count

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer has 165 citations in the OpenAlex counts ScholarIQ stores.

When was European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer published?

ScholarIQyear

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer has 2021 year in the ScholarIQ index.

What is the open-access status of European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer?

ScholarIQoa status

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer has bronze oa status in the ScholarIQ index.

What is the DOI of European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer?

ScholarIQdoi

The DOI for European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer is on the source record.

What is the PMID of European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer?

ScholarIQpmid

The PMID for European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer is on the source record.

What is the OpenAlex record for European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer?

ScholarIQopenalex

The OpenAlex for European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial